KalVista initiates KONFIDENT-KID trial for on-demand treatment of hereditary angioedema attacks with sebetralstat in children aged 2 to 11 KalVista...
Vous n'êtes pas connecté
- English
- Français
- عربي
- Español
- Deutsch
- Português
- русский язык
- Català
- Italiano
- Nederlands, Vlaams
- Norsk
- فارسی
- বাংলা
- اردو
- Azərbaycan dili
- Bahasa Indonesia
- Հայերեն
- Ελληνικά
- Bosanski jezik
- українська мова
- Íslenska
- Türkmen, Түркмен
- Türkçe
- Shqip
- Eesti keel
- magyar
- Қазақ тілі
- Kalaallisut ; kalaallit oqaasii
- Lietuvių kalba
- Latviešu valoda
- македонски јазик
- Монгол
- Bahasa Melayu ; بهاس ملايو
- ဗမာစာ
- Slovenščina
- тоҷикӣ ; toğikī ; تاجیکی
- ไทย
- O'zbek ; Ўзбек ; أۇزبېك
- Tiếng Việt
- ភាសាខ្មែរ
- རྫོང་ཁ
- Soomaaliga ; af Soomaali
Rubriques :
Maroc - HAEI.ORG - A La Une - 18/Jun 10:03
KalVista Submits New Drug Application to FDA for Sebetralstat as First Oral On-demand Treatment for HAE
KalVista Submits New Drug Application to FDA for Sebetralstat as First Oral On-demand Treatment for Hereditary Angioedema KalVista Pharmaceuticals, Inc, today announced the submission of a New Drug Application (NDA) for US Food and Drug Administration (FDA) review of sebetralstat, a novel investigational oral plasma kallikrein inhibitor for the on-demand treatment of hereditary angioedema [...]
Articles similaires
SpringWorks (SWTX) Completes NDA Submission for Mirdametinib
zacks.com - 02/Jul 16:12
SpringWorks (SWTX) completes the submission of a new drug application for its MEK inhibitor, mirdametinib, for treating patients with...
SpringWorks (SWTX) Completes NDA Submission for Mirdametinib
zacks.com - 02/Jul 16:12
SpringWorks (SWTX) completes the submission of a new drug application for its MEK inhibitor, mirdametinib, for treating patients with...
SpringWorks Therapeutics Completes Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PN
drugs.com - 01/Jul 06:07
STAMFORD, Conn., July 01, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused...
Vertex Announces FDA Acceptance of New Drug Application for Vanzacaftor/Tezacaftor/Deutivacaftor, a Next-In-Class Triple Combination Treatment for Cystic Fibrosis
mangaloremirror.com - 02/Jul 12:37
– Vanza triple granted priority review with Prescription Drug User Fee Act (PDUFA) target action date of January 2, 2025 – – EU...
Synaptogenix gets US FDA authorization of IND application for clinical trial for Bryostatin─1 to treat multiple sclerosis
pharmabiz.com - 01/Jul 00:00
Synaptogenix, Inc., an emerging biopharmaceutical company developing therapeutics for neurodegenerative disorders, announced that the Food & Drug...
Vertex (VRTX) NDA for Vanza Triple Therapy Accepted by FDA
zacks.com - 13:13
The FDA accepts Vertex's (VRTX) new drug application for vanza triple therapy for people living with cystic fibrosis aged six years and above. A...
New Strategy to Enhance Checkpoint Inhibitor Therapy for Cancer
medindia.net - 27/Jun 16:00
Introducing a novel approach to enhance checkpoint inhibitor therapy for cancer, promising improved treatment outcomes and efficacy in clinical...
AbbVie Provides U.S. Regulatory Update on ABBV-951 (Foscarbidopa/Foslevodopa)
drugs.com - 25/Jun 21:06
NORTH CHICAGO, Ill., June 25, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced it received a Complete Response Letter (CRL) from the U.S. Food...
FDA Approves Augtyro for NTRK-Positive Advanced Solid Tumors
drugs.com - 20/Jun 20:47
THURSDAY, June 20, 2024 -- The U.S. Food and Drug Administration has approved Augtyro (repotrectinib), a next-generation tyrosine kinase inhibitor...
Les derniers communiqués
-
Aucun élément